As previously mentioned, TET2 loss of function mutations are frequently found in patients with myeloid malignancies, myeloproliferative disorders (MPN), or myelodysplastic syndromes (MDS) (Table 1). This evidence concerns the gene TET2 and myelodysplastic syndrome.